Geographic Atrophy (GA) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Geographic Atrophy (GA) Market Outlook

Thelansis’s “Geographic Atrophy (GA) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Geographic atrophy treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Geographic Atrophy (GA) Overview

Geographic atrophy (GA) marks the advanced stage of the dry variant of age-related macular degeneration (AMD). Some individuals with AMD may develop GA, characterized by the deterioration and death of cells in specific regions of the retina. The border of GA signifies the endpoint of continuous retinal pigment epithelium (RPE), with an internal absence of RPE cells, although a few are scattered within the GA area. Initial manifestations of AMD include drusen and irregularities in the retinal pigment epithelium (RPE). This early stage, known as age-related maculopathy (ARM), may progress to GA or exudative AMD. Around 11% of atrophic AMD, patients transition to the exudative form after four years. Choroidal neovascularization (CNV) in some eyes can also lead to GA. The intricate pathophysiology of GA involves chronic inflammation from an overactivated complement system, resulting in the loss of photoreceptors, RPE, and the underlying choriocapillaris. The disappearance of these structures manifests as well-defined atrophic lesions characteristic of GA. Diagnosis relies on visual function tests for assessing impairments and imaging tests for identifying clinical features, as there are no laboratory or genetic tests for GA. Historically, no treatment existed for GA until the recent FDA approval of intravitreal pegcetacoplan for GA secondary to AMD. Given the irreversible nature of vision loss in GA, treatment aims to decelerate lesion growth. Ongoing research focuses on potential drugs to slow lesion growth and preserve retinal tissue in the long term.

• In the United States, GA prevalence is 3.5% in individuals aged over 65, constituting approximately half the prevalence of exudative AMD.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: